GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NexGel Inc (NAS:NXGL) » Definitions » EV-to-FCF

NXGL (NexGel) EV-to-FCF : -5.29 (As of Mar. 16, 2025)


View and export this data going back to 2021. Start your Free Trial

What is NexGel EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, NexGel's Enterprise Value is $21.44 Mil. NexGel's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-4.05 Mil. Therefore, NexGel's EV-to-FCF for today is -5.29.

The historical rank and industry rank for NexGel's EV-to-FCF or its related term are showing as below:

NXGL' s EV-to-FCF Range Over the Past 10 Years
Min: -8.28   Med: -2.85   Max: -0.15
Current: -5.29

During the past 8 years, the highest EV-to-FCF of NexGel was -0.15. The lowest was -8.28. And the median was -2.85.

NXGL's EV-to-FCF is ranked worse than
100% of 378 companies
in the Medical Devices & Instruments industry
Industry Median: 27.27 vs NXGL: -5.29

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-16), NexGel's stock price is $2.789. NexGel's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.590. Therefore, NexGel's PE Ratio (TTM) for today is At Loss.


NexGel EV-to-FCF Historical Data

The historical data trend for NexGel's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NexGel EV-to-FCF Chart

NexGel Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial - - -1.81 -0.79 -3.25

NexGel Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.02 -3.25 -4.13 -4.08 -4.94

Competitive Comparison of NexGel's EV-to-FCF

For the Medical Instruments & Supplies subindustry, NexGel's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NexGel's EV-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NexGel's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where NexGel's EV-to-FCF falls into.



NexGel EV-to-FCF Calculation

NexGel's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=21.444/-4.054
=-5.29

NexGel's current Enterprise Value is $21.44 Mil.
NexGel's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NexGel  (NAS:NXGL) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

NexGel's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.789/-0.590
=At Loss

NexGel's share price for today is $2.789.
NexGel's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.590.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


NexGel EV-to-FCF Related Terms

Thank you for viewing the detailed overview of NexGel's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


NexGel Business Description

Traded in Other Exchanges
N/A
Address
2150 Cabot Boulevard West, Suite B, Langhorne, PA, USA, 19047
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating, and cross-linking technologies.
Executives
Scott Robert Henry director 34A ATLANTIC AVE., COHASSET MA 02025
Adam R. Levy officer: CEO and President 2 AVENUE OF TWO RIVER SOUTH, RUMSON NJ 07760
Jerome B Zeldis director 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Drapczuk Adam E Iii officer: Chief Financial Officer 6 OAKMONT TERRACE, EAST WINDSOR NJ 08520
Steven Mark Glassman director 99 LEWIS POINT ROAD, FAIR HAVEN NJ 07704
Nachum Stein director QUADRAX CORP, 618 MAIN ST PO BOX 1001, WEST WARWICK RI 02893
David Stefansky director 850 THIRD AVENUE, SUITE 1801, NEW YORK NY 10022
Yaakov Spinrad director 3450 OAKTON ST, SKOKIE IL 60076
Miranda Jayne Toledano director C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135
Bezalel Partners Llc 10 percent owner C/O KRIEGER & PRAGER LLP, 39 BROADWAY, STE 920, NEW YORK NY 10006
David Ian Johnson director, officer: Chief Executive Officer C/O ALLIQUA, INC., 850 3RD AVENUE, 18TH FLOOR, NEW YORK NY 10022
Adynxx, Inc. 10 percent owner 100 PINE ST., STE. 500, SAN FRANCISCO CA 94111